Skip to main content
Premium Trial:

Request an Annual Quote

GenMark Enters Into $65M Loan and Security Agreement

NEW YORK (GenomeWeb) – GenMark Diagnostics said on Wednesday that it entered into a loan and security agreement on Feb. 1 through which Solar Capital is providing it with up to $65 million in a series of term loans.

In a filing with the US Securities and Exchange Commission, GenMark said that under the terms of the agreement, it had an option to borrow $50 million on Feb. 1 as part of a Tranche 1 Loan. It can borrow an additional $15 million no later than Dec. 31, 2019, should GenMark achieve a designated threshold amount of product revenues on a trailing six-month basis.

In the SEC filing, GenMark said that on Feb. 1, it used about $38.8 million of the Tranche 1 Loan proceeds to repay all outstanding principal, interest, related fees, and other obligations under its existing loan and security agreement with Solar Senior Capital, dated Jan. 12, 2015.

Under the agreement, the term loans will accrue interest at a floating per annum rate in effect from time-to-time equal to the greater of 2.51 percent or the one-month LIBOR rate in effect as of the applicable payment date, plus 5.90 percent per annum.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.